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Abstract
The ability to regulate any protein of interest in living systems with small molecules remains a
challenge. We hypothesized that appending a hydrophobic moiety to the surface of a protein
would mimic the partially denatured state of the protein, thus engaging the cellular quality control
machinery to induce its proteasomal degradation. We designed and synthesized bifunctional small
molecules that bind a bacterial dehalogenase (HaloTag protein) and present a hydrophobic group
on its surface. Remarkably, hydrophobic tagging of the HaloTag protein with an adamantyl moiety
induced the degradation of cytosolic, isoprenylated, and transmembrane fusion proteins in cell
culture. We demonstrated the in vivo utility of hydrophobic tagging by degrading proteins
expressed in zebrafish embryos and by inhibiting RasG12V-driven tumor progression in mice.
Therefore, hydrophobic tagging of HaloTag fusion proteins affords small molecule control over
any protein of interest, making it an ideal system for validating potential drug targets in disease
models.
Introduction
One of the central challenges of chemical biology remains the ability to perturb the function
of any intracellular protein using a small molecule. While significant strides have been made
towards developing individual ligands to specific proteins, only approximately 300
molecular targets for approved drugs have been characterized1. Furthermore, the fraction of
the proteome classified as “undruggable” by current methods is estimated to be about 80%2.
It is likely that many appealing drug candidates have yet to be found and that future
advances in drug development will be able to overcome the boundaries of what is thought to
be an “undruggable” target3,4. Therefore, the challenge for biologists remains to identify
those disease-causing drug targets. To this end, advances in deep sequencing, microarray
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technology and genome-wide RNAi screens have been employed successfully to identify
promising new drug targets. For instance, genome-wide RNAi screens have been employed
to identify synthetic lethal interactions with mutated oncogenes and to identify genes
necessary for various pathogenic infections5-7.
While target identification is an obvious important first step in drug development, the in vivo
validation of these potential targets remains a challenge. This is due in part to the
unpredictable pharmacokinetics/pharmacodynamics of any inhibitory compound identified
based on in vitro inhibition of protein function. In other words, is the failure of a small
molecule inhibitor to give the desired in vivo result an unforeseen consequence of its in vivo
metabolism or is its target protein simply a poor drug target? To address this question,
general methods are needed to functionally validate whether modulation of a putative
disease-relevant protein leads to the desired in vivo result. RNAi offered initial promise for
organismal validation of putative drug targets, however, the delivery and stability of duplex
RNA remain major hurdles in knocking down mRNA expression in a whole animal setting8.
In the absence of a direct ligand for the target protein, there are currently three categories of
small molecule-based methods to control the function of a protein of interest (POI)9. First,
the plant hormone auxin can be employed to dimerize a plant E3 ubiquitin ligase (TIR1)
with a domain from the AUX/IAA transcriptional repressor (Aid1), which when fused to a
POI can be ubiquitinated by proximity to TIR110. This method requires fusing the POI to
Aid1, along with an introduction of the plant E3 ligase TIR1 into cells. A second general
method used to deregulate protein function involves dimerization of FKBP12 and the
FKBP12-rapamycin binding (FRB) domain from mTOR. It has been shown that a POI can
be recruited to the proteasome or to the mitochondrial outer membrane by this method11-13.
Again, at least two fusion proteins must be introduced into the cell for this system to
function9. Lastly, two destabilizing domains (DDs), one based on the FKBP12 protein and
the other on E. coli DHFR protein14,15, have been developed to destabilize a DD-POI fusion
protein. The degradation conferring DD can be stabilized by inclusion of derivatives of
FK50616 (in the case of mutagenized FKBP12) or the E. coli DHFR inhibitor trimethoprim
(in the case of DHFR), ultimately leading to increased levels of the fusion protein. While the
DD method has been successfully used in several studies17-20, it requires the continued
presence of the ligand for stable expression of the fusion protein. This requirement can be a
concern when studying developing embryos, which might not receive sufficient stabilizing
ligand, or when studying the long term effects of a POI, in which case the ligand would have
to be injected into an animal for the duration of the study. Also, in the case of the long-term
expression of the POI, one must bear in mind the possible fluctuations of the POI levels that
are due to the intermittent injections of the stabilizing ligand.
To develop a general method to degrade any intracellular protein using a small molecule, we
sought to enlist the cellular protein quality control machinery. The burial of internal
hydrophobic residues within a protein's core is a major driving force behind protein folding,
and, correspondingly, exposure of such hydrophobic regions is considered a hallmark of an
unfolded protein21-23. For instance, the endoplasmic reticulum Hsp70-class chaperone BiP
specifically binds hydrophobic amino acids and helps slow-folding proteins to fold22,24.
Should the cell fail to fold the target protein correctly, the unfolded protein is eliminated by
either the ubiquitin-proteasome system or autophagy25. We sought to mimic the partially
denatured state of a protein by appending a hydrophobic tag on its surface in order to induce
its degradation. To test this hypothesis, we selected the HaloTag dehalogenase system
developed by Promega as the fusion protein component26. This system was chosen because
HaloTag fusion proteins are commercially available in various formats and the haloalkane
reactive linker binds to the HaloTag domain covalently, suggesting a high specificity of the
ligand for HaloTag. Here, we demonstrate that hydrophobic tagging affords rapid and robust
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control of the abundance of numerous proteins, including transmembrane receptors, in
cultured cells as well as in zebrafish and mouse models.
Results
Hydrophobic tagging destabilizes HaloTag fusion proteins
We designed 21 structurally distinct scaffolds as the basis for our Hydrophobic Tags
(HyTs), and synthesized and tested 30 compounds across these scaffolds composed of
hydrophobic moieties linked to the HaloTag haloalkane reactive linker (Supplementary
Table 1). In designing the hydrophobic portion of these bifunctional molecules, we used the
compound library available in the Yale University Small Molecule Discovery Center as an
informal resource to identify compounds that (1) maximized hydrophobicity, (2) minimized
molecular weight, and (3) incorporated chemically diverse and commercially available
scaffolds. To determine their biological activity, we generated a stable HEK 293T cell line
expressing a luciferase-HaloTag fusion protein and treated these cells with the HyT
compounds at 1 μM for 24 hours. Remarkably, several non-toxic compounds appeared to
reduce luciferase activity and we characterized the five most potent compounds further (Fig.
1a). All five HyTs exhibited high hydrophobicity scores (logP ranging from +3 to +5) and
were active in a concentration-dependent manner, whereas the HyT5 control compound with
two PEG groups did not decrease the luciferase activity (Fig. 1b). Based on these initial
data, we continued our investigation of hydrophobic tagging-induced degradation with
hydrophobic containing HyT13 because of the reported high stability and cell permeability
of compounds bearing adamantyl groups27,28.
As our luciferase assay relied on the loss-of-activity of the luciferase-HaloTag fusion
protein, we wanted to determine whether the decrease in luciferase activity resulted from the
degradation of the entire fusion protein or perhaps simply inhibition of luciferase activity.
We generated a stable Flp-In 293 cell line with a single integration site containing HA-
EGFP-HaloTag fusion protein, and employed this cell line to perform kinetic studies with
HyT13. Immunoblotting showed that HyT13 efficiently degraded the fusion protein, with a
maximal effect achieved at 100 nM (Fig. 2a). The IC50 of HyT13 was determined to be 21
nM (Supplementary Results, Supplementary Fig. 1). A time course experiment revealed that
the full effect is reached within 8 hours, with 50% degradation observed by 1.5 hours (Fig.
2b and Supplementary Fig. 2). When cells were treated with 1 μM HyT13 for 24 hours, and
then the HyT13 was removed for 24 hours, the protein level recovered to half the starting
levels. No cellular toxicity was observed at 20 μM of HyT13, a dose of 1000-fold over the
IC50 value (Supplementary Fig. 3). Consistent with our hypothesis that hydrophobic tagging
mimics a partially denatured protein state and that the protein is ultimately delivered to the
proteasome for degradation, inclusion of proteasome inhibitors MG132 and YU10129
blocked HyT13 mediated degradation (Fig. 2c). To verify that the observed decrease in HA-
EGFP-HaloTag levels does not result from masking of the HA epitope during
immunoblotting, we generated a HeLa cell line stably expressing EGFP-HaloTag and
analyzed the intracellular fluorescence by flow cytometry. Consistent with our previous
observations, treatment of these cells with 1 μM of HyT13 for 24 hours reduced the mean
fluorescence intensity of cells almost 7-fold (Fig. 2d). Together, these findings provide the
first experimental evidence that hydrophobic tagging represents a viable strategy for the
control of protein levels.
Degradation of transmembrane and zebrafish proteins
One limitation of existing technologies for small molecule control of protein levels has been
the difficulty of degrading transmembrane proteins9. To determine if hydrophobic tagging
shares this limitation, we constructed several transmembrane-HA-HaloTag fusion proteins,
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such that the HaloTag portion would be intracellular. Ror2 is a single-pass receptor tyrosine
kinase-like orphan receptor, which functions in Wnt ligand signaling30. Likewise, CD3E is a
single-pass cell surface glycoprotein involved in antigen recognition31. CD9 is a 4-pass
transmembrane protein from the tetraspanin family and it functions in integrin signaling32.
Finally, G-protein coupled receptors GPR40 and Frizzled-4 are 7-pass transmembrane
receptors for long-chain free fatty acids and Wnt proteins, respectively33,34. Treatment of
HEK 293T cell lines stably expressing these transmembrane HaloTag fusion proteins with
HyT13 efficiently induced their degradation (Fig. 2e), demonstrating the potential of our
hydrophobic tagging system to degrade transmembrane proteins. These experiments show
that fusions to either the amino or carboxy terminus of the HaloTag protein are susceptible
to this small molecule-induced degradation strategy and that transmembrane proteins can be
degraded by HyT13.
We also explored the possibility of employing the hydrophobic tagging system in the
zebrafish Danio rerio. We injected HA-HaloTag-Smad5 cRNA into zebrafish embryos and
then treated the embryos with either vehicle or HyT13. Immunoblotting of injected embryo
lysates revealed that the fusion protein is very efficiently degraded, demonstrating that
HyT13 is able to penetrate the chorion and can direct the HaloTag fusion proteins for
degradation in zebrafish (Fig. 2f). These experiments show that HyT13 is capable of
degrading fusion proteins in various cell lines, as well as in zebrafish embryos.
HyT13 suppresses HaloTag-RasG12V tumor burden in mice
We next explored the functional utility of HaloTag-based degradation of an oncogene by
HyT13 both in cell culture and in mice. The small GTPase H-Ras is one of the most
commonly mutated genes in cancer, with up to 90% of cancers harboring activating
mutations in this gene35. Activating mutations, such as the H-RasG12V allele, lead to
decreased dependence on extracellular mitogenic signals. Ectopic expression of H-RasG12V
in mouse fibroblast cell line NIH-3T3 can lead to a transformed phenotype, as demonstrated
by assays in cell culture and in mice. When H-RasG12V expressing cells are grown in
culture under low serum conditions they lose cell-to-cell contact inhibition and form distinct
foci instead of growing as a cellular monolayer. Furthermore, these transformed cells are
capable of tumor formation when injected into immuno-compromised nude mice36,37. We
investigated whether (1) HaloTag-H-RasG12V driven focus formation can be suppressed in
NIH-3T3 cells and (2) HaloTag-H-RasG12V driven tumor burden in mice can be reduced by
administration of HyT13. First, NIH-3T3 cells were stably infected with a HA-HaloTag-H-
RasG12V retroviral construct. The encoded fusion protein was readily degraded with HyT13
(Fig. 3a). To test the HaloTag receptor specificity for HyT13, we generated a point mutation
in the HaloTag protein (HaloTagD106A) that is unable to form a covalent bond with the
reactive chloroalkane in HyT1326. Unlike HA-HaloTag-H-RasG12V, HA-
HaloTag(D106A)-H-RasG12V fusion protein was unaffected by HyT13 (Fig. 3a). Next, we
plated both cell lines sparsely (105 cells/10-cm plate) in 10% FBS containing media. The
next day, the media was replaced with 1% FBS containing media and the cultures were
treated with either vehicle or HyT13. By day 6, both vehicle-treated cell lines and HyT13-
treated HA-HaloTag(D106A)-H-RasG12V expressing cells had formed many foci, whereas
HA-HaloTag-H-RasG12V expressing cells treated with HyT13 had grown a normal
monolayer of cells, much like the parental NIH-3T3 cells (Fig. 3b-c). In the absence of
HyT13, HA-HaloTag-H-RasG12V expressing cells exhibited slightly higher number of
colonies than HA-HaloTag(D106A)-H-RasG12V cells. However, we attribute this
observation to slight differences in retroviral infection efficiencies, since we have observed
instances where the HaloTag(D106A)-H-RasG12V cells exhibit more colonies than the HA-
HaloTag-H-RasG12V cells as well (data not shown). These results demonstrate that
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hydrophobic tagging can be used to reduce protein activity in the context of in vitro cell
culture.
To examine whether the HaloTag:HyT13 based system could be used in mouse models to
relieve the H-RasG12V-driven tumor burden, we first evaluated the pharmacokinetics of
HyT13. We performed a maximum tolerated dose experiment with HyT13 in nude mice at
doses up to 100 mg/kg over a 14-day treatment regimen. No obvious phenotype was
observed even at the highest dose (Supplementary Fig. 4). Next, we sought to determine the
serum bioavailability of HyT13 following injections. HyT13 was administered at 25 mg/kg
by intraperitoneal (IP) injection into Swiss Webster mice and the serum was collected at 1
and 24 hours post-injection. At 1 hour post HyT13 administration the blood serum
concentration was approximately 2 μM, and by 24 hours the HyT13 concentration had
dropped to about 500 nM (Supplementary Fig. 5). Based on our previous experiments in a
cell culture setting, we speculated that these serum HyT13 concentrations would be
sufficient to suppress H-RasG12V tumor formation in mice. To test this, we injected
NIH-3T3 cells expressing HA-HaloTag-H-RasG12V into the flank of nude mice and on the
same day started a daily treatment regimen of vehicle, 25 mg/kg HyT13 or 100 mg/kg
HyT13. Obvious solid tumor masses were observed on day 9 in vehicle-treated mice and the
tumor volume grew exponentially until day 13, when the animals were sacrificed. The
tumors in HyT13 mice were on average 6 times smaller than in vehicle treated mice,
suggesting that HyT13 was able to reduce H-RasG12V tumor formation (Fig. 3d). These
data clearly demonstrate the utility of the HaloTag:HyT13 system in perturbing protein
function in live animals.
Discussion
Here we describe a novel hydrophobic tagging technology to systematically degrade levels
of a specific protein upon addition of a small molecule (Fig. 4). This strategy has several
benefits over the existing technologies. First, protein degradation is achieved upon
compound administration as opposed to following ligand withdrawal. This aspect is
particularly relevant when a protein needs to be expressed for long periods before the study,
as there is no continuous ligand treatment necessary to maintain expression of the POI. In
contrast, DD-based methods (see Introduction) of controlling protein abundance require
constant drug administration, which can be both time-consuming and expensive. Also, there
are likely fluctuations in the concentration of the fusion protein between ligand
administrations using the DD-based system, whereas the expression of the HaloTag fusion
protein is stable in the absence of the degradation signal. Therefore, depending on the
application, it can be desirable to have a system where the small molecule induces
degradation, rather than stabilization, of the POI. Second, our HaloTag:HyT13 method relies
on the single introduction of a fusion domain to the POI. This feature contrasts with the
auxin system, where an exogenous plant E3 ligase must be expressed in addition to the
fusion protein. Third, almost all human and mouse genes are commercially available as both
N- and C-terminal HaloTag fusions in transient and lentiviral expression vectors. These
protein fusions with the 34 kDa HaloTag receptor are proving useful in many studies of
protein function since they can be readily labeled in vivo and purified using fluorescent or
biotinylated HaloTag reagents. The ability to degrade these fusion proteins with the
hydrophobic tag HyT13 only adds to the repertoire of possible HaloTag applications.
Although HyT13 is not yet commercially available, this small molecule can be obtained
using standard synthetic methods in four steps from commercially available starting
materials with an overall yield of 63% (see Supplementary Methods – Scheme 2).
One of the criticisms that surround the several FKBP12 based degradation systems is their
reliance on either rapamycin, FK506 or their derivatives to cause protein perturbation. Since
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these are bioactive small molecules, they could induce biological effects unrelated to
perturbing the POI. In contrast, HaloTag dehalogenase is a bacterial gene and covalent
binding of HyT13 to HaloTag affords this system a high degree of specificity. This
bioorthogonality may explain the lack of noticeable HyT13 cytotoxicity even upon 1,000-
fold administration over its IC50 value of 21 nM in cell culture. Moreover, mice injected
daily with HyT13 at 100 mg/kg for 14 days gained weight normally, suggesting that HyT13
possesses no in vivo toxicity even at this high dose.
Like several other systematic degradation methods, the HaloTag:HyT13 methodology is not
able to degrade endogenous proteins unless the HaloTag gene is fused with the gene of
interest. However, there are two viable strategies to overcome this limitation and subject
endogenous proteins to Halotag:HyT13-mediated regulation in culture or live animals. First,
it is possible to generate HaloTag fusion constructs via targeted genome engineering. Recent
advances in zinc finger nucleases20,38,39 and homologous recombination40 technologies
open the possibility of systematically tagging endogenous proteins in rodents in a manner
similar to yeast. The second approach would be to inactivate the endogenous gene by
knockdown or knockout techniques and introduce the corresponding HaloTag fusion gene
into the animal. Both approaches should be amenable to bypassing an early requirement of
an essential gene, thus allowing the study of its function later during organogenesis or
disease development.
In summary, herein we describe a chemical biology approach to systematically degrade any
POI in either cell culture or whole animals. The system requires construction of a single
fusion protein, which is specifically degraded by the addition of a non-toxic, low-molecular
weight hydrophobic tag. We believe this system is particularly amenable to animal studies,
as we have shown here with experiments in zebrafish and mice. Additionally, our findings
suggest that hydrophobic tagging represents a novel approach to promote targeted
degradation of endogenous proteins independent of the HaloTag:HyT13 system.
Methods
Synthesis and characterization of HyT compounds is described in Supplementary
Methods
Cell culture and materials—Indicated cells were grown at 37°C in DMEM,
supplemented with 10% fetal bovine serum and penicillin/streptomycin. The HaloTag
protein was obtained from pHT2 vector (Promega). The luciferase sequence was obtained
from pGL3-Basic vector (Promega), mouse Ror2 was kindly provided by Sigmar Stricker
(Max Planck-Institute for Molecular Genetics), Danio rerio Smad5 was cloned from a
zebrafish cDNA library and H-RasG12V was obtained from Addgene plasmid 9051,
contributed by Robert Weinberg (MIT). The remaining transmembrane proteins were cloned
from a human spleen cDNA library (Invitrogen). A D106A point mutation was introduced
into the HaloTag gene by the QuikChange Site Directed mutagenesis kit (Stratagene). Flp-In
293 cells were purchased from Invitrogen. HA-HaloTag-Smad5 and EGFP-HaloTag were
cloned into the pCS2+ vector, while the rest of the constructs were cloned into a retroviral
pEYK3.1 vector (kindly provided by George Daley, MIT) by excising GFP41. Retrovirus
was generated in GP2-293 cells (Clontech) with a pVSV-G and a corresponding pEYK
plasmid, and the indicated cells were infected as described41. Anti-HA antibody was
purchased from Covance (clone 16B12) and anti-β-actin antibody was purchased from
Sigma (clone AC-74). HyT compounds were stored and aliquoted in DMSO as 1000× stock
solutions.
Luciferase assay—Ten thousand stable HEK 293T cells infected with HA-luciferase-
HaloTag were plated into each well in a 96-well plate. The next day, indicated HyT
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compounds were added in triplicate and the cells were cultured for another 24 hours. The
cells were washed once with cold PBS and lysed in Passive Lysis Buffer (Promega). The
luciferase activity was performed by Steady-Glo Luciferase Assay System (Promega) on a
Wallac Victor 2 Plate Reader (Perkin Elmer) and the luciferase activity was normalized by
protein concentration, as determined by the Bradford assay.
Immunoblotting—The indicated cells were washed twice with cold PBS and the cells
were lysed in lysis buffer (1× PBS, 1% NP-40, 1 mM EDTA, 40 mM HEPES) with protease
inhibitors. The lysates were cleared by centrifugation at 10,000 g for 5 min. The total protein
concentration was determined by Bradford assay and 50 μg of protein was loaded onto an
8% Bis-Tris gel. To solubilize polyubiquitinated and aggregated proteins upon proteasome
inhibition42 samples generated for Fig. 2e were lysed with a SDS lysis buffer (1× PBS, 1%
NP-40, 1% SDS, 1% sodium deoxycholate, 1 mM EDTA, 40mM HEPES) with protease
inhibitors. The blots were processed by standard procedures with indicated antibodies, and
the band intensities were quantified by ImageJ.
Flow cytometry analysis—Stable HeLa cells were raised by cotransfection of pCS2/
EGFP-HaloTag and p-Puro containing the puromycin resistance gene. A clonal population
of cells expressing EGFP-HaloTag was isolated. These cells were treated with vehicle or 1
μM HyT13 for 24 hours, washed with PBS and trypsinized. The cells were resuspended in
FBS-free DMEM and the intracellular GFP level was measured by FACSCalibur (BD
Biosciences).
Zebrafish Danio rerio experiments—The wild-type fish line TLF was used for this
study. The HA-HaloTag-Smad5 in pCS2+ plasmid was in vitro transcribed with the SP6
transcription kit (Ambion). The mRNA was injected at 100 ng/μL at the one cell stage and
embryos were raised to the 256-cell stage, when they were moved to glass depression slides
(10-per-well) and put in 1 ml E2 media with or without HyT13 (10 μM). Embryos were
cultured at 28.6°C for 24 hours and then dechorionated and de-yolked as described43.
Approximately 60 embryos per condition were collected for immunoblot analysis, as
described above.
Focus formation assay—One hundred thousand NIH-3T3 cells infected with HA-
HaloTag-H-RasG12V and HA-HaloTag(D106A)-H-RasG12V were plated onto 10-cm cell
culture plates in 10% FBS with DMEM. The next day, the media was replaced with 1% FBS
media and the cells were administered either vehicle or 1 μM HyT13. The media and the
drug were replaced every two days. On day 6, the foci were photographed and counted as
the number of distinct foci per 1-cm2 area.
Tumor formation assay—One hundred thousand NIH-3T3 cells expressing HA-
HaloTag-H-RasG12V were injected into the flank of anesthetized 6-week old female nu/nu
nude mice (Charles River Laboratories). Two hours later, the mice were IP injected with
either vehicle (10 μL volume, with 5 μL DMSO and 5 μL of Cremophor EL), 25 mg/kg
HyT13 or 100 mg/kg HyT13. The drug injections continued daily until the end of the
experiment. Upon the appearance of tumors on day 7, the tumors were measured daily with
calipers, and their volumes were calculated using the formula: a(b)2 / 2, where a and b
represent the longest and shortest diameters of the tumor, respectively.
Animal experiments—All experimental protocols involving zebrafish and mouse work
were performed under the auspices of Yale University's Institutional Animal Care and Use
Committee (IACUC).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hydrophobic tagging strategy using the HaloTag fusion protein system
(a) Chemical structures of the representative HaloTag Ligands: HyT5, HyT12, HyT13,
HyT16, HyT21 and HyT22. (b) HEK 293T cells expressing HA-HaloTag-luciferase were
treated with indicated compounds at 1 μM for 24 hours, at which point luciferase assays
were performed.
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Figure 2. HyT13 leads to degradation of HaloTag fusion proteins
(a) Flp-In 293 cells expressing HA-EGFP-HaloTag were treated with indicated
concentrations of HyT13 for 24 hours. The lysates were probed with anti-HA and anti-β-
actin antibodies. (b) The same cell line as in (a) was treated for the indicated times with 1
μM HyT13. The rightmost sample was treated with HyT13 for 24 hours, after which HyT13-
free media was provided for 24 hours. (c) The same cell line as in (a) was pretreated with
proteasome inhibitors MG132 (10 μM) and YU101 (10 μM) for 1 hour prior to addition of 1
μM HyT13. The lysates were prepared from cells 6 hours after HyT13 addition. (d) HeLa
cells stably expressing EGFP-HaloTag were treated with vehicle or 1 μM HyT13 for 24
hours, whereupon the intracellular GFP fluorescence was quantified by flow cytometry. MFI
= mean fluorescence intensity. (e) HEK 293T cells stably expressing indicated
transmembrane HA-HaloTag fusion proteins were treated with 1 μM HyT13 for 24 hours.
Shown are representative images from at least three experiments; bands were quantified and
mean degradation ± SEM is shown. (f) One-cell stage zebrafish embryos were injected with
100 ng of HA-HaloTag-Smad5 cRNA, grown to 256-cell stage and then treated with 10 μM
HyT13 for 24 hours. Shown are representative images from at least three experiments; bands
were quantified and mean degradation ± SEM is shown. Full gels are available in
Supplementary Results.
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Figure 3. Functional validation of HaloTag degradation by HyT13
(a) NIH-3T3 cells were retrovirally infected with a construct expressing either HA-HaloTag-
HRas(G12V) or HA-HaloTag(D106A)-HRas(G12V). The cells were then treated with
vehicle or 1 μM HyT13 for 24 hours. The lysates were prepared for immunoblotting and the
blots were probed with anti-HA and anti-β-actin antibodies. Full gels are available in
Supplementary Results. (b) One hundred thousand NIH-3T3 cells infected with HA-
HaloTag-HRas(G12V) or HA-HaloTag(D106A)-HRas(G12V) were plated in 10% FBS
containing medium onto 10-cm plates. The next day, the medium was replaced with 1%
FBS containing medium, along with vehicle or 1 μM HyT13. The media was refreshed
every 2 days, and the plates were pictured on day 6. Bar, 5 mm. (c) Quantification of foci as
described in (b). The number of foci/cm2 was counted from three separate plates, with error
bars representing SEM. (d) One hundred thousand HA-HaloTag-HRasG12V-expressing
NIH-3T3 cells were injected into the flank of nude mice on day 0. The mice were
administered IP injections of vehicle or HyT13 daily from day 0. Tumor size was measured
daily, and the tumor volume was calculated. Each treatment group employed 7 mice. Error
bars represent SEM.
Neklesa et al. Page 13
Nat Chem Biol. Author manuscript; available in PMC 2012 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Schematic of HyT13 mediated degradation of HaloTag fusion proteins
A fusion protein composed of a protein of interest and the HaloTag protein is degraded upon
HyT13 treatment by the proteasome.
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